
APPENDIX D

DETAILED TABLES ON FINANCIAL EFFECTS AND NPV OF NSPs

		1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
NSP Expenditure											
Total Govt NSP Expend		-\$8,482,805	-\$9,229,559	-\$9,830,915	-\$10,588,542	-\$11,127,279	-\$12,341,186	-\$15,005,665	-\$16,353,751	-\$17,505,049	-\$19,673,115
All NSP Expend		-\$9,573,954	-\$10,412,793	-\$11,438,420	-\$12,493,700	-\$12,992,474	-\$13,896,572	-\$17,048,446	-\$18,979,078	-\$20,434,694	-\$22,674,291
HIV Effects - Cases Avoided											
CD4 >500	Diagnosed	544	887	1,369	2,033	2,950	4,213	5,935	8,255	11,320	15,277
CD4 <500	Diagnosed	47	107	210	373	616	1,004	1,573	2,399	3,585	5,266
AIDS	Diagnosed	10	23	44	78	131	192	278	393	540	725
Total Diag. HIV Cases Avoided		601	1,017	1,623	2,484	3,697	5,409	7,786	11,047	15,445	21,268
Annual Treatment Costs-HIV											
CD4>500		\$1,520,716	\$2,479,550	\$3,826,950	\$5,683,119	\$8,246,532	\$11,777,166	\$30,683,950	\$42,678,350	\$58,524,400	\$78,982,090
CD4<500		\$211,430	\$481,341	\$944,687	\$1,677,944	\$2,771,082	\$4,516,505	\$13,612,742	\$20,760,946	\$31,024,590	\$45,571,964
AIDS		\$837,771	\$1,926,874	\$3,686,194	\$6,534,616	\$10,974,805	\$16,085,210	\$13,882,473	\$19,625,223	\$26,965,955	\$36,204,291
Total HIV Costs Avoided		\$2,569,918	\$4,887,765	\$8,457,831	\$13,895,679	\$21,992,419	\$32,378,880	\$58,179,165	\$83,064,519	\$116,514,945	\$160,758,345
Net Govt Expenditure/Savings		-\$5,912,888	-\$4,341,794	-\$1,373,084	\$3,307,137	\$10,865,140	\$20,037,694	\$43,173,500	\$66,710,768	\$99,009,896	\$141,085,230
Net All Expend/Savings		-\$7,004,036	-\$5,525,028	-\$2,980,589	\$1,401,979	\$8,999,946	\$18,482,308	\$41,130,719	\$64,085,440	\$96,080,251	\$138,084,054
HIV	NPV Govt Expend @ 5%		All Years	\$2,276,548,829		NPV All Expend @ 5%		All Years	\$2,261,898,701		
			To 2000	\$241,702,597				To 2000	\$227,052,469		
	NPV Govt Expend @ 3%		All Years	\$3,414,541,497		NPV All Expend @ 3%		All Years	\$3,398,079,560		
			To 2000	\$286,631,780				To 2000	\$270,169,843		
	NPV Govt Expend @ 0%		All Years	\$6,895,585,578		NPV All Expend @ 0%		All Years	\$6,875,779,022		
			To 2000	\$372,561,599				To 2000	\$352,755,044		

	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
HCV Effects - Cases Avoided										
Stage 0/1 Diagnosed	2,233	2,822	3,419	4,031	4,663	5,321	6,011	6,737	7,505	8,321
Stage 2/3 Diagnosed	132	200	279	372	477	595	727	872	1,031	1,205
Cirrhosis Diagnosed	3	6	11	18	26	37	51	68	88	112
HCC Diagnosed	0	0	0	0	0	0	1	1	1	1
Liver Failure Diagnosed	0	0	1	1	1	2	2	3	4	5
Total Diag. HCV Cases Avoided	2,368	3,028	3,710	4,422	5,167	5,955	6,792	7,681	8,629	9,644
Whole of HCV Episode Costs	\$123,272	\$157,517	\$192,752	\$229,499	\$267,914	\$308,362	\$351,207	\$396,607	\$444,925	\$496,527
Annual Treatment Costs-HCV										
Stage 0/1	\$453,299	\$572,866	\$694,057	\$818,293	\$946,589	\$1,080,163	\$1,220,233	\$1,367,611	\$1,523,515	\$1,689,163
Stage 2/3	\$26,796	\$40,600	\$56,637	\$75,516	\$96,831	\$120,785	\$147,581	\$177,016	\$209,293	\$244,615
Cirrhosis	\$1,140	\$2,280	\$4,180	\$6,840	\$9,880	\$14,060	\$19,380	\$25,840	\$33,440	\$42,560
HCC	\$0	\$0	\$0	\$0	\$0	\$0	\$100,770	\$100,770	\$100,770	\$100,770
Liver Failure	\$0	\$0	\$167,109	\$167,109	\$167,109	\$334,219	\$334,219	\$501,328	\$668,438	\$835,547
Total HCV Costs Avoided	\$604,507	\$773,263	\$1,114,736	\$1,297,258	\$1,488,324	\$1,857,589	\$2,173,390	\$2,569,172	\$2,980,381	\$3,409,182
Total Costs Avoided HIV + HCV	\$3,174,425	\$5,661,028	\$9,572,567	\$15,192,937	\$23,480,743	\$34,236,469	\$60,352,555	\$85,633,691	\$119,495,325	\$164,167,527
Net Govt Expenditure/Savings	-\$5,308,381	\$3,568,531	-\$258,349	\$4,604,395	\$12,353,463	\$21,895,283	\$45,346,890	\$69,279,940	\$101,990,277	\$144,494,413
Net All Expend/Savings	-\$6,399,529	\$4,751,765	-\$1,865,853	\$2,699,237	\$10,488,269	\$20,339,897	\$43,304,109	\$66,654,612	\$99,060,631	\$141,493,236
HIV+HCV	NPV Govt Expend @ 5%	All Years	\$2,401,575,004	NPV All Expend @ 5%	All Years	\$2,386,924,875				
		To 2000	\$254,859,826		To 2000	\$240,209,698				
	NPV Govt Expend @ 3%	All Years	\$3,653,324,247	NPV All Expend @ 3%	All Years	\$3,636,862,310				
		To 2000	\$301,576,093		To 2000	\$285,114,155				
	NPV Govt Expend @ 0%	All Years	\$7,678,155,690	NPV All Expend @ 0%	All Years	\$7,658,349,135				
		To 2000	\$390,829,399		To 2000	\$371,022,844				

		2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
NSP Expenditure											
Total Govt NSP Expend											
All NSP Expend											
HIV Effects - Cases Avoided											
CD4 >500	Diagnosed	12,681	9,833	7,142	4,896	3,230	2,105	1,363	876	560	356
CD4 <500	Diagnosed	7,551	10,027	12,247	13,901	14,865	15,196	15,094	14,733	14,210	13,603
AIDS	Diagnosed	946	1,219	1,521	1,834	2,130	2,392	2,602	2,746	2,828	2,849
Total Diag. HIV Cases Avoided		21,178	21,079	20,910	20,631	20,225	19,693	19,059	18,355	17,598	16,808
Annual Treatment Costs-HIV											
CD4>500		\$65,560,770	\$50,836,610	\$36,924,140	\$25,312,320	\$16,699,100	\$10,882,850	\$7,046,710	\$4,528,920	\$2,895,200	\$1,840,520
CD4<500		\$65,346,354	\$86,773,658	\$105,985,538	\$120,299,254	\$128,641,710	\$131,506,184	\$130,623,476	\$127,499,382	\$122,973,340	\$117,720,362
AIDS		\$47,240,358	\$60,873,146	\$75,954,106	\$91,584,372	\$106,365,711	\$119,449,192	\$129,935,953	\$137,126,874	\$141,221,704	\$142,270,380
Total HIV Costs Avoided		\$178,147,482	\$198,483,414	\$218,863,784	\$237,195,946	\$251,706,521	\$261,838,226	\$267,606,139	\$269,155,176	\$267,090,244	\$261,831,262

		2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
HCV Effects - Cases Avoided											
Stage 0/1	Diagnosed	8,068	7,823	7,586	7,359	7,143	6,937	6,741	6,556	6,379	6,212
Stage 2/3	Diagnosed	1,367	1,516	1,654	1,782	1,901	2,012	2,116	2,213	2,304	2,389
Cirrhosis	Diagnosed	139	170	204	241	281	324	369	416	465	517
HCC	Diagnosed	2	2	3	3	3	4	5	5	6	6
Liver Failure	Diagnosed	6	8	9	11	12	14	16	18	20	22
Total Diag. HCV Cases Avoided		9,582	9,519	9,456	9,396	9,340	9,291	9,247	9,208	9,174	9,146
Whole of HCV Episode Costs		\$491,784	\$486,780	\$481,620	\$476,460	\$471,404	\$466,452	\$461,657	\$457,070	\$452,587	\$448,313
Annual Treatment Costs-HCV											
Stage 0/1		\$1,637,804	\$1,588,069	\$1,539,958	\$1,493,877	\$1,450,029	\$1,408,211	\$1,368,423	\$1,330,868	\$1,294,937	\$1,261,036
Stage 2/3		\$277,501	\$307,748	\$335,762	\$361,746	\$385,903	\$408,436	\$429,548	\$449,239	\$467,712	\$484,967
Cirrhosis		\$52,820	\$64,600	\$77,520	\$91,580	\$106,780	\$123,120	\$140,220	\$158,080	\$176,700	\$196,460
HCC		\$201,539	\$201,539	\$302,309	\$302,309	\$302,309	\$403,079	\$503,848	\$503,848	\$604,618	\$604,618
Liver Failure		\$1,002,656	\$1,336,875	\$1,503,985	\$1,838,203	\$2,005,313	\$2,339,532	\$2,673,751	\$3,007,969	\$3,342,188	\$3,676,407
Total HCV Costs Avoided		\$3,664,105	\$3,985,612	\$4,241,154	\$4,564,176	\$4,721,738	\$5,148,830	\$5,577,447	\$5,907,075	\$6,338,743	\$6,671,801
Total Costs Avoided HIV + HCV		\$181,811,587	\$202,469,026	\$223,104,938	\$241,760,122	\$256,428,259	\$266,987,056	\$273,183,586	\$275,062,251	\$273,428,987	\$268,503,064

		2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
NSP Expenditure											
Total Govt NSP Expend											
All NSP Expend											
HIV Effects - Cases Avoided											
CD4 >500	Diagnosed	225	141	88	55	34	21	13	8	5	3
CD4 <500	Diagnosed	12,958	12,296	11,638	10,996	10,375	9,781	9,214	8,677	8,165	7,679
AIDS	Diagnosed	2,824	2,762	2,674	2,569	2,453	2,331	2,208	2,086	1,968	1,855
Total Diag. HIV Cases Avoided		16,007	15,199	14,400	13,620	12,862	12,133	11,435	10,771	10,138	9,537
Annual Treatment Costs-HIV											
CD4>500		\$1,163,250	\$728,970	\$454,960	\$284,350	\$175,780	\$108,570	\$67,210	\$41,360	\$25,850	\$15,510
CD4<500		\$112,138,532	\$106,409,584	\$100,715,252	\$95,159,384	\$89,785,250	\$84,644,774	\$79,737,956	\$75,090,758	\$70,659,910	\$66,454,066
AIDS		\$141,021,956	\$137,925,865	\$133,531,413	\$128,288,033	\$122,495,347	\$116,403,038	\$110,260,793	\$104,168,485	\$98,275,924	\$92,633,048
Total HIV Costs Avoided		\$254,323,738	\$245,064,419	\$234,701,625	\$223,731,767	\$212,456,377	\$201,156,382	\$190,065,959	\$179,300,603	\$168,961,684	\$159,102,624

		2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
HCV Effects - Cases Avoided											
Stage 0/1	Diagnosed	6,054	5,905	5,765	5,634	5,511	5,397	5,284	5,173	5,063	4,955
Stage 2/3	Diagnosed	2,469	2,544	2,616	2,683	2,748	2,810	2,867	2,919	2,966	3,008
Cirrhosis	Diagnosed	570	625	682	740	800	862	924	987	1,051	1,115
HCC	Diagnosed	7	8	8	9	10	11	11	12	13	14
Liver Failure	Diagnosed	24	27	29	31	34	36	39	42	44	47
Total Diag. HCV Cases Avoided		9,124	9,109	9,100	9,097	9,103	9,116	9,125	9,133	9,137	9,139
Whole of HCV Episode Costs		\$444,248	\$440,391	\$436,846	\$433,510	\$430,487	\$427,777	\$424,858	\$421,783	\$418,499	\$415,059
Annual Treatment Costs-HCV											
Stage 0/1	Diagnosed	\$1,228,962	\$1,198,715	\$1,170,295	\$1,143,702	\$1,118,733	\$1,095,591	\$1,072,652	\$1,050,119	\$1,027,789	\$1,005,865
Stage 2/3	Diagnosed	\$501,207	\$516,432	\$531,048	\$544,649	\$557,844	\$570,430	\$582,001	\$592,557	\$602,098	\$610,624
Cirrhosis	Diagnosed	\$216,600	\$237,500	\$259,160	\$281,200	\$304,000	\$327,560	\$351,120	\$375,060	\$399,380	\$423,700
HCC	Diagnosed	\$705,388	\$806,158	\$806,158	\$906,927	\$1,007,697	\$1,108,467	\$1,108,467	\$1,209,236	\$1,310,006	\$1,410,776
Liver Failure	Diagnosed	\$4,010,626	\$4,511,954	\$4,846,173	\$5,180,392	\$5,681,720	\$6,015,939	\$6,517,267	\$7,018,595	\$7,352,814	\$7,854,142
Total HCV Costs Avoided		\$7,107,030	\$7,711,149	\$8,049,680	\$8,490,380	\$9,100,481	\$9,545,763	\$10,056,364	\$10,667,350	\$11,110,586	\$11,720,166
Total Costs Avoided HIV + HCV		\$261,430,769	\$252,775,568	\$242,751,305	\$232,222,147	\$221,556,858	\$210,702,145	\$200,122,323	\$189,967,953	\$180,072,270	\$170,822,790

		2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
NSP Expenditure											
Total Govt NSP Expend											
All NSP Expend											
HIV Effects - Cases Avoided											
CD4 >500	Diagnosed	2	1	1	0	0	0	0	0	0	0
CD4 <500	Diagnosed	7,219	6,784	6,371	5,980	5,610	5,258	4,925	4,608	4,307	4,021
AIDS	Diagnosed	1,747	1,644	1,546	1,453	1,365	1,281	1,202	1,127	1,056	988
Total Diag. HIV Cases Avoided		8,968	8,429	7,918	7,433	6,975	6,539	6,127	5,735	5,363	5,009
Annual Treatment Costs-HIV											
CD4>500		\$10,340	\$5,170	\$5,170	\$0	\$0	\$0	\$0	\$0	\$0	\$0
CD4<500		\$62,473,226	\$58,708,736	\$55,134,634	\$51,750,920	\$48,548,940	\$45,502,732	\$42,620,950	\$39,877,632	\$37,272,778	\$34,797,734
AIDS		\$87,239,857	\$82,096,351	\$77,202,530	\$72,558,393	\$68,163,941	\$63,969,237	\$60,024,218	\$56,278,946	\$52,733,423	\$49,337,710
Total HIV Costs Avoided		\$149,723,423	\$140,810,257	\$132,342,334	\$124,309,313	\$116,712,881	\$109,471,969	\$102,645,168	\$96,156,578	\$90,006,201	\$84,135,444

		2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
HCV Effects - Cases Avoided											
Stage 0/1	Diagnosed	4,847	4,741	4,635	4,530	4,425	4,321	4,216	4,112	4,007	3,902
Stage 2/3	Diagnosed	3,046	3,079	3,107	3,131	3,149	3,163	3,172	3,176	3,175	3,168
Cirrhosis	Diagnosed	1,179	1,243	1,306	1,369	1,432	1,493	1,552	1,611	1,667	1,721
HCC	Diagnosed	14	15	16	17	18	18	19	20	20	21
Liver Failure	Diagnosed	49	52	55	57	60	62	65	67	69	71
Total Diag. HCV Cases Avoided		9,135	9,130	9,119	9,104	9,084	9,057	9,024	8,986	8,938	8,883
Whole of HCV Episode Costs		\$411,410	\$407,605	\$403,539	\$399,317	\$394,783	\$390,092	\$385,088	\$379,875	\$374,350	\$368,512
Annual Treatment Costs-HCV											
Stage 0/1	Diagnosed	\$983,941	\$962,423	\$940,905	\$919,590	\$898,275	\$877,163	\$855,848	\$834,736	\$813,421	\$792,106
Stage 2/3	Diagnosed	\$618,338	\$625,037	\$630,721	\$635,593	\$639,247	\$642,089	\$643,916	\$644,728	\$644,525	\$643,104
Cirrhosis	Diagnosed	\$448,020	\$472,340	\$496,280	\$520,220	\$544,160	\$567,340	\$589,760	\$612,180	\$633,460	\$653,980
HCC	Diagnosed	\$1,410,776	\$1,511,545	\$1,612,315	\$1,713,085	\$1,813,854	\$1,813,854	\$1,914,624	\$2,015,394	\$2,015,394	\$2,116,164
Liver Failure	Diagnosed	\$8,188,361	\$8,689,689	\$9,191,017	\$9,525,236	\$10,026,565	\$10,360,783	\$10,862,112	\$11,196,330	\$11,530,549	\$11,864,768
Total HCV Costs Avoided		\$12,060,846	\$12,668,640	\$13,274,778	\$13,713,041	\$14,316,884	\$14,651,321	\$15,251,347	\$15,683,244	\$16,011,699	\$16,438,634
Total Costs Avoided HIV + HCV		\$161,784,269	\$153,478,897	\$145,617,112	\$138,022,355	\$131,029,765	\$124,123,291	\$117,896,515	\$111,839,822	\$106,017,900	\$100,574,078

	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	
NSP Expenditure											
Total Govt NSP Expend											
All NSP Expend											
HIV Effects - Cases Avoided											
CD4 >500	Diagnosed	0	0	0	0	0	0	0	0	0	
CD4 <500	Diagnosed	3,750	3,492	3,248	3,016	2,796	2,587	2,388	2,199	2,021	1,851
AIDS	Diagnosed	924	864	806	751	699	650	603	558	516	476
Total Diag. HIV Cases Avoided		4,674	4,356	4,054	3,767	3,495	3,237	2,991	2,757	2,537	2,327
Annual Treatment Costs-HIV											
CD4>500		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
CD4<500		\$32,452,500	\$30,219,768	\$28,108,192	\$26,100,464	\$24,196,584	\$22,387,898	\$20,665,752	\$19,030,146	\$17,489,734	\$16,018,554
AIDS		\$46,141,745	\$43,145,528	\$40,249,184	\$37,502,652	\$34,905,930	\$32,459,020	\$30,111,983	\$27,864,820	\$25,767,468	\$23,769,990
Total HIV Costs Avoided		\$78,594,245	\$73,365,296	\$68,357,376	\$63,603,116	\$59,102,514	\$54,846,918	\$50,777,735	\$46,894,966	\$43,257,202	\$39,788,544

		2031	2032	2033	2034	2035	2036	2037	2038	2039	2040
HCV Effects - Cases Avoided											
Stage 0/1	Diagnosed	3,796	3,690	3,582	3,474	3,364	3,253	3,140	3,026	2,911	2,793
Stage 2/3	Diagnosed	3,157	3,140	3,117	3,089	3,055	3,015	2,969	2,917	2,859	2,794
Cirrhosis	Diagnosed	1,772	1,820	1,865	1,906	1,943	1,975	2,002	2,023	2,038	2,047
HCC	Diagnosed	22	22	23	23	24	24	25	25	25	25
Liver Failure	Diagnosed	74	75	77	79	80	81	82	83	84	84
Total Diag. HCV Cases Avoided		8,821	8,747	8,664	8,571	8,466	8,348	8,218	8,074	7,917	7,743
Whole of HCV Episode Costs		\$362,414	\$356,003	\$349,175	\$342,086	\$334,580	\$326,709	\$318,422	\$309,769	\$300,752	\$291,213
Annual Treatment Costs-HCV											
Stage 0/1		\$770,588	\$749,070	\$727,146	\$705,222	\$682,892	\$660,359	\$637,420	\$614,278	\$590,933	\$566,979
Stage 2/3		\$640,871	\$637,420	\$632,751	\$627,067	\$620,165	\$612,045	\$602,707	\$592,151	\$580,377	\$567,182
Cirrhosis		\$673,360	\$691,600	\$708,700	\$724,280	\$738,340	\$750,500	\$760,760	\$768,740	\$774,440	\$777,860
HCC		\$2,216,933	\$2,216,933	\$2,317,703	\$2,317,703	\$2,418,473	\$2,418,473	\$2,519,242	\$2,519,242	\$2,519,242	\$2,519,242
Liver Failure		\$12,366,096	\$12,533,206	\$12,867,424	\$13,201,643	\$13,368,753	\$13,535,862	\$13,702,972	\$13,870,081	\$14,037,190	\$14,037,190
Total HCV Costs Avoided		\$17,030,262	\$17,184,232	\$17,602,899	\$17,918,001	\$18,163,202	\$18,303,948	\$18,541,523	\$18,674,262	\$18,802,935	\$18,759,667
Total Costs Avoided HIV + HCV		\$95,624,507	\$90,549,527	\$85,960,275	\$81,521,117	\$77,265,717	\$73,150,866	\$69,319,258	\$65,569,228	\$62,060,137	\$58,548,211

	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050
NSP Expenditure										
Total Govt NSP Expend										
All NSP Expend										
HIV Effects - Cases Avoided										
CD4 >500	Diagnosed	0	0	0	0	0	0	0	0	0
CD4 <500	Diagnosed	1,690	1,539	1,395	1,260	1,132	1,013	901	796	699
AIDS	Diagnosed	438	402	368	336	305	276	249	224	200
Total Diag. HIV Cases Avoided		2,128	1,941	1,763	1,596	1,437	1,289	1,150	1,020	899
Annual Treatment Costs-HIV										
CD4>500		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
CD4<500		\$14,625,260	\$13,318,506	\$12,072,330	\$10,904,040	\$9,796,328	\$8,766,502	\$7,797,254	\$6,888,584	\$6,049,146
AIDS		\$21,872,386	\$20,074,655	\$18,376,799	\$16,778,816	\$15,230,771	\$13,782,599	\$12,434,301	\$11,185,878	\$9,987,391
Total HIV Costs Avoided		\$36,497,646	\$33,393,161	\$30,449,129	\$27,682,856	\$25,027,099	\$22,549,101	\$20,231,555	\$18,074,462	\$16,036,537

		2041	2042	2043	2044	2045	2046	2047	2048	2049	2050
HCV Effects - Cases Avoided											
Stage 0/1	Diagnosed	2,674	2,554	2,432	2,308	2,183	2,057	1,930	1,803	1,675	1,548
Stage 2/3	Diagnosed	2,723	2,645	2,561	2,471	2,375	2,272	2,164	2,051	1,933	1,811
Cirrhosis	Diagnosed	2,048	2,042	2,029	2,007	1,976	1,937	1,889	1,832	1,766	1,691
HCC	Diagnosed	25	25	25	25	24	24	23	22	22	21
Liver Failure	Diagnosed	84	83	83	82	80	78	76	74	71	68
Total Diag. HCV Cases Avoided		7,554	7,349	7,130	6,893	6,638	6,368	6,082	5,782	5,467	5,139
Whole of HCV Episode Costs		\$281,310	\$270,990	\$260,252	\$249,098	\$237,578	\$225,642	\$213,393	\$200,884	\$188,061	\$175,082
Annual Treatment Costs-HCV											
Stage 0/1		\$542,822	\$518,462	\$493,696	\$468,524	\$443,149	\$417,571	\$391,790	\$366,009	\$340,025	\$314,244
Stage 2/3		\$552,769	\$536,935	\$519,883	\$501,613	\$482,125	\$461,216	\$439,292	\$416,353	\$392,399	\$367,633
Cirrhosis		\$778,240	\$775,960	\$771,020	\$762,660	\$750,880	\$736,060	\$717,820	\$696,160	\$671,080	\$642,580
HCC		\$2,519,242	\$2,519,242	\$2,519,242	\$2,519,242	\$2,418,473	\$2,418,473	\$2,317,703	\$2,216,933	\$2,216,933	\$2,116,164
Liver Failure		\$14,037,190	\$13,870,081	\$13,870,081	\$13,702,972	\$13,368,753	\$13,034,534	\$12,700,315	\$12,366,096	\$11,864,768	\$11,363,440
Total HCV Costs Avoided		\$18,711,574	\$18,491,670	\$18,434,174	\$18,204,109	\$17,700,958	\$17,293,496	\$16,780,313	\$16,262,435	\$15,673,267	\$14,979,143
Total Costs Avoided HIV + HCV		\$55,209,219	\$51,884,831	\$48,883,303	\$45,886,965	\$42,728,057	\$39,842,597	\$37,011,869	\$34,336,897	\$31,709,803	\$29,138,207

	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060
NSP Expenditure										
Total Govt NSP Expend										
All NSP Expend										
HIV Effects - Cases Avoided										
CD4 >500	Diagnosed	0	0	0	0	0	0	0	0	0
CD4 <500	Diagnosed	526	451	382	320	265	217	175	139	109
AIDS	Diagnosed	157	137	119	103	88	75	63	52	42
Total Diag. HIV Cases Avoided		683	588	501	423	353	292	238	191	151
Annual Treatment Costs-HIV										
CD4>500		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
CD4<500		\$4,552,004	\$3,902,954	\$3,305,828	\$2,769,280	\$2,293,310	\$1,877,918	\$1,514,450	\$1,202,906	\$943,286
AIDS		\$7,840,102	\$6,841,363	\$5,942,497	\$5,143,506	\$4,394,452	\$3,745,272	\$3,146,028	\$2,596,722	\$2,097,352
Total HIV Costs Avoided		\$12,392,106	\$10,744,317	\$9,248,325	\$7,912,786	\$6,687,762	\$5,623,190	\$4,660,478	\$3,799,628	\$3,040,638

		2051	2052	2053	2054	2055	2056	2057	2058	2059	2060
HCV Effects - Cases Avoided											
Stage 0/1	Diagnosed	1,422	1,297	1,176	1,057	942	832	728	631	541	458
Stage 2/3	Diagnosed	1,686	1,559	1,431	1,302	1,175	1,051	930	815	706	605
Cirrhosis	Diagnosed	1,609	1,519	1,423	1,322	1,217	1,110	1,001	894	789	689
HCC	Diagnosed	20	19	17	16	15	14	12	11	10	8
Liver Failure	Diagnosed	64	60	56	52	48	43	39	34	30	26
Total Diag. HCV Cases Avoided		4,801	4,454	4,103	3,749	3,397	3,050	2,710	2,385	2,076	1,786
Whole of HCV Episode Costs		\$162,000	\$148,864	\$135,886	\$122,959	\$110,345	\$98,148	\$86,421	\$75,370	\$64,998	\$55,407
Annual Treatment Costs-HCV											
Stage 0/1		\$288,666	\$263,291	\$238,728	\$214,571	\$191,226	\$168,896	\$147,784	\$128,093	\$109,823	\$92,974
Stage 2/3		\$342,258	\$316,477	\$290,493	\$264,306	\$238,525	\$213,353	\$188,790	\$165,445	\$143,318	\$122,815
Cirrhosis		\$611,420	\$577,220	\$540,740	\$502,360	\$462,460	\$421,800	\$380,380	\$339,720	\$299,820	\$261,820
HCC		\$2,015,394	\$1,914,624	\$1,713,085	\$1,612,315	\$1,511,545	\$1,410,776	\$1,209,236	\$1,108,467	\$1,007,697	\$806,158
Liver Failure		\$10,695,002	\$10,026,565	\$9,358,127	\$8,689,689	\$8,021,252	\$7,185,705	\$6,517,267	\$5,681,720	\$5,013,282	\$4,344,845
Total HCV Costs Avoided		\$14,114,740	\$13,247,041	\$12,277,058	\$11,406,200	\$10,535,353	\$9,498,678	\$8,529,878	\$7,498,815	\$6,638,938	\$5,684,018
Total Costs Avoided HIV + HCV		\$26,506,845	\$23,991,358	\$21,525,384	\$19,318,987	\$17,223,115	\$15,121,867	\$13,190,356	\$11,298,443	\$9,679,576	\$8,108,811

	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070
NSP Expenditure										
Total Govt NSP Expend										
All NSP Expend										
HIV Effects - Cases Avoided										
CD4 >500	Diagnosed	0	0	0	0	0	0	0	0	0
CD4 <500	Diagnosed	63	47	35	25	18	12	8	5	2
AIDS	Diagnosed	27	21	16	12	8	6	4	2	1
Total Diag. HIV Cases Avoided		90	68	51	37	26	18	12	7	3
Annual Treatment Costs-HIV										
CD4>500		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
CD4<500		\$545,202	\$406,738	\$302,890	\$216,350	\$155,772	\$103,848	\$69,232	\$43,270	\$17,308
AIDS		\$1,348,298	\$1,048,676	\$798,991	\$599,243	\$399,496	\$299,622	\$199,748	\$99,874	\$49,937
Total HIV Costs Avoided		\$1,893,500	\$1,455,414	\$1,101,881	\$815,593	\$555,268	\$403,470	\$268,980	\$143,144	\$67,245

		2061	2062	2063	2064	2065	2066	2067	2068	2069	2070
HCV Effects - Cases Avoided											
Stage 0/1	Diagnosed	383	316	256	204	160	124	94	70	51	36
Stage 2/3	Diagnosed	511	427	349	281	223	173	133	99	73	52
Cirrhosis	Diagnosed	593	504	420	344	277	219	170	130	97	70
HCC	Diagnosed	7	6	5	4	3	3	2	2	1	1
Liver Failure	Diagnosed	22	19	15	12	10	8	6	4	3	2
Total Diag. HCV Cases Avoided		1,516	1,272	1,045	845	673	527	405	305	225	161
Whole of HCV Episode Costs		\$46,598	\$38,728	\$31,535	\$25,280	\$19,963	\$15,481	\$11,832	\$8,809	\$6,463	\$4,587
Annual Treatment Costs-HCV											
Stage 0/1		\$77,749	\$64,148	\$51,968	\$41,412	\$32,480	\$25,172	\$19,082	\$14,210	\$10,353	\$7,308
Stage 2/3		\$103,733	\$86,681	\$70,847	\$57,043	\$45,269	\$35,119	\$26,999	\$20,097	\$14,819	\$10,556
Cirrhosis		\$225,340	\$191,520	\$159,600	\$130,720	\$105,260	\$83,220	\$64,600	\$49,400	\$36,860	\$26,600
HCC		\$705,388	\$604,618	\$503,848	\$403,079	\$302,309	\$302,309	\$201,539	\$201,539	\$100,770	\$100,770
Liver Failure		\$3,676,407	\$3,175,079	\$2,506,641	\$2,005,313	\$1,671,094	\$1,336,875	\$1,002,656	\$668,438	\$501,328	\$334,219
Total HCV Costs Avoided		\$4,835,215	\$4,160,774	\$3,324,439	\$2,662,847	\$2,176,375	\$1,798,176	\$1,326,709	\$962,493	\$670,593	\$484,039
Total Costs Avoided HIV + HCV		\$6,728,715	\$5,616,188	\$4,426,321	\$3,478,440	\$2,731,643	\$2,201,646	\$1,595,689	\$1,105,637	\$737,838	\$484,039

	2071	2072	2073	2074	2075	Total
NSP Expenditure						
Total Govt NSP Expend						-\$130,137,868
All NSP Expend						-\$149,944,423
HIV Effects - Cases Avoided						
CD4 >500	Diagnosed					96,422
CD4 <500	Diagnosed					344,734
AIDS	Diagnosed					71,410
Total Diag. HIV Cases Avoided						512,566
Annual Treatment Costs-HIV						
CD4>500						\$470,016,453
CD4<500						\$2,973,533,547
AIDS						\$3,582,173,445
Total HIV Costs Avoided						\$7,025,723,445
Net Govt Expenditure/Savings						\$6,895,585,578
Net All Expend/Savings						\$6,875,779,022

		2071	2072	2073	2074	2075	Total
HCV Effects - Cases Avoided							
Stage 0/1	Diagnosed	24	15	9	4	0	285,367
Stage 2/3	Diagnosed	35	23	13	6	0	150,916
Cirrhosis	Diagnosed	48	31	18	8	0	79,585
HCC	Diagnosed	1	0	0	0	0	975
Liver Failure	Diagnosed	1	1	0	0	0	3,248
Total Diag. HCV Cases Avoided		109	70	40	18	0	520,091
Whole of HCV Episode Costs		\$3,075	\$1,981	\$1,147	\$521	\$0	\$22,740,552
Annual Treatment Costs-HCV							
Stage 0/1		\$4,872	\$3,045	\$1,827	\$812	\$0	\$57,929,501
Stage 2/3		\$7,105	\$4,669	\$2,639	\$1,218	\$0	\$30,635,948
Cirrhosis		\$18,240	\$11,780	\$6,840	\$3,040	\$0	\$30,242,300
HCC		\$100,770	\$0	\$0	\$0	\$0	\$98,250,451
Liver Failure		\$167,109	\$167,109	\$0	\$0	\$0	\$542,771,360
Total HCV Costs Avoided		\$301,171	\$188,584	\$12,453	\$5,591	\$0	\$782,570,112
Total Costs Avoided HIV + HCV		\$301,171	\$188,584	\$12,453	\$5,591	\$0	\$7,808,293,558
Net Govt Expenditure/Savings		\$301,171	\$188,584	\$12,453	\$5,591	\$0	\$7,678,155,690
Net All Expend/Savings		\$301,171	\$188,584	\$12,453	\$5,591	\$0	\$7,658,349,135

